Skip to main content

Buprenorphine Sublingual Tablets Shortage

Last Updated: May 26, 2016
Status: Resolved

Products Affected - Description
    • Buprenorphine sublingual tablet, Teva, 2 mg, 30 count, NDC 00093-5378-56
    • Buprenorphine sublingual tablet, Teva, 8 mg, 30 count, NDC 00093-5379-56
Reason for the Shortage
    • Teva could not provide a reason for the shortage.
    • Akorn acquired Hi-Tech Pharmacal in 2014.
Available Products
    • Buprenorphine sublingual tablet, Akorn, 2 mg, 30 count, NDC 50383-0930-93
    • Buprenorphine sublingual tablet, Akorn, 8 mg, 30 count, NDC 50383-0924-93
    • Buprenorphine sublingual tablet, Roxane, 2 mg, 30 count, NDC 00054-0176-13
    • Buprenorphine sublingual tablet, Roxane, 8 mg, 30 count, NDC 00054-0177-13

Estimated Resupply Dates

    • Teva has buprenorphine 2 mg and 8 mg sublingual tablets temporarily unavailable and the company cannot estimate a release date.
    • Akorn and Roxane have had product available for several months.


Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 18, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.